mc4r deficiency obesity
Tirzepatide vs Semaglutide MC4R Deadly Gap Uncovered
In a 12-week head-to-head trial tirzepatide trimmed an average of 9.1 kg, making it the most potent GLP-1-based obesity drug available today. This superiority reflects its dual GLP-1/GIP mechanism, while semaglutide and the emerging triple-agonist retatrutide occupy distinct niches. As prescription options expand, clinicians must match each molecule